News

Video

Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2

Author(s):

Tanios Bekaii-Saab, MD

A phase 3, randomized, double-blind, placebo-controlled study to determine if prior TAS-102 and/or regorafenib treatment status and sequence affect the efficacy and safety of fruquintinib in patients with mCRC. This study used data from both FRESCO (NCT02314819) and FRESCO-2 (NCT04322539).

Related Videos
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Kimmie Ng, MD, MPH
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD
Josep Llovet, MD
Cathy Eng, MD, FACP, FASCO
Kimmie Ng, MD, MPH
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Related Content
Thierry André, MD
October 16th 2024

Accurate Diagnosis of dMMR/MSI-H Status Is Key for Nivolumab/Ipilimumab Treatment in mCRC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Todd Aguilera, MD, PhD, assistant professor, radiation oncology, UT Southwestern Medical Center
October 10th 2024

Sotigalimab May Be a Safe and Feasible Addition to the Rectal Cancer Chemoradiotherapy Paradigm

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

FDA
October 4th 2024

FDA Approves Cologuard Plus for Adults at Average Risk for CRC

State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH
October 2nd 2024

State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH